The Li Ka Shing Foundation announced on 11 November 2026 that it would provide 30 places in a kidney-cancer clinical trial using Histotripsy at CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital.
The technology uses sound waves to break up tumours; HK01 described it as non-invasive.
The kidney-cancer programme extends local use of the technology beyond liver and pancreatic tumours. The Foundation’s reported figures put the number of patients in Hong Kong treated with or benefiting from Histotripsy at more than 400 over the previous two years.
The kidney-cancer programme is separate from pancreatic-cancer trials already under way at Gleneagles and CUHK Medical Centre. The Foundation said Gleneagles’ trial began on 31 March 2026 and had completed 20 pancreatic-tumour cases by the announcement. The CUHK Medical Centre trial began on 3 June and had completed six.